Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by Sanford C. Bernstein from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, Marketbeat reports.

TEVA has been the topic of a number of other research reports. Oppenheimer Holdings, Inc. set a $43.00 price objective on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, April 6th. Credit Suisse Group set a $39.00 price objective on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a research report on Monday, July 24th. Finally, Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. One research analyst has rated the stock with a sell rating, twenty-two have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and a consensus price target of $39.81.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 13.26% during mid-day trading on Friday, reaching $20.60. The company’s stock had a trading volume of 93,317,085 shares. The stock has a market cap of $20.93 billion, a P/E ratio of 264.10 and a beta of 0.46. The stock has a 50 day moving average of $32.05 and a 200-day moving average of $32.28. Teva Pharmaceutical Industries Limited has a one year low of $20.41 and a one year high of $55.45. Teva Pharmaceutical Industries Limited also was the target of unusually large options trading on Thursday. Traders acquired 66,716 put options on the company. This is an increase of approximately 864% compared to the typical daily volume of 6,922 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.18% and a negative net margin of 25.18%. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same period in the prior year, the company posted $1.25 EPS. The firm’s revenue was up 12.9% compared to the same quarter last year. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.65 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/06/teva-pharmaceutical-industries-limited-teva-rating-lowered-to-market-perform-at-sanford-c-bernstein.html.

Several large investors have recently made changes to their positions in the company. RiverPoint Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries Limited by 9.1% in the second quarter. RiverPoint Capital Management LLC now owns 15,836 shares of the company’s stock valued at $526,000 after buying an additional 1,325 shares during the period. Federated Investors Inc. PA increased its stake in shares of Teva Pharmaceutical Industries Limited by 34,112.9% in the second quarter. Federated Investors Inc. PA now owns 228,542 shares of the company’s stock valued at $7,592,000 after buying an additional 227,874 shares during the period. FCA Corp TX acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at $266,000. Boston Private Wealth LLC increased its stake in shares of Teva Pharmaceutical Industries Limited by 21.8% in the second quarter. Boston Private Wealth LLC now owns 10,472 shares of the company’s stock valued at $348,000 after buying an additional 1,871 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its stake in shares of Teva Pharmaceutical Industries Limited by 1.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 42,611 shares of the company’s stock valued at $1,416,000 after buying an additional 611 shares during the period. Institutional investors and hedge funds own 56.20% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.